UNSPSC 51352006: Levonorgestrel

This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W7SIA7YZW, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)- but generally known as levonorgestrel, which bears US NIH Compound Identifier 13109. European Medicines Agency schedules Levonorgestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08483MIG.

UNSPSC 51352006 Levonorgestrel is a Commodity code covering the supply of this specific hormonal contraceptive and emergency contraceptive product to state and local health systems, correctional facilities, public health agencies, and cooperative purchasing consortia. State and local governments procure levonorgestrel as part of broader pharmaceutical supply agreements that bundle generic, multi-source medications and over-the-counter products through authorized wholesale distributors. Issuing bodies include state health departments, state purchasing offices administering cooperative agreements, and participating local government health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—a multi-state consortium administered by the Minnesota Department of Administration's Office of State Procurement—represents a primary buying mechanism, aggregating demand across member states including Oregon and other jurisdictions to negotiate volume pricing and standardize product specifications across participating entities.

The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, with responses due March 26, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026. Vendors must supply levonorgestrel and other identified products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and submit pricing in multiple formats (flat price, net price, or WAC-minus structures). The RFP weighted evaluation 75 percent on price competitiveness, with the remainder on administrative compliance, EDI capability, insurance coverage requirements (commercial general liability of $5,000,000 per occurrence), cGMP certification, and Drug Supply Chain Security Act compliance. Contract term runs two years for new vendors with optional extensions, and MMCAP reserves multi-award discretion based on therapeutic considerations and member-specific needs. No specific set-aside designations were identified in the solicitation.